Clinical trial · Interventional
Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer
Prospective, Randomized, Open-label, Controlled Trial of Cyclooxygenase-2 Inhibitor (Celecoxib; Celebrex®) for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer.
NCT01111591CI-TRIAL-00024492unknownPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In extrahepatic bile duct cancer and pancreatic cancer, we will treat postoperatively with COX2 inhibitor and assess survival rate and recurrent rate.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bile Duct Cancer | Malignant Bile Duct Neoplasm | CURATED_BROADER | 0.80 |
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cox2 inhibitor (Celecoxib) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- NO_INTERVENTION
- label
- 2. Bile duct cancer - control
- description
- Bile duct cancer patients do not administration of COX inhibitor
- type
- EXPERIMENTAL
- label
- 3. Pancreas cancer - experimental
- description
- Pancreas cancer patients take a COX2 inhibitor 200mg every 12hours for 6 months
- interventionNames
- Drug: Cox2 inhibitor (Celecoxib)
- type
- NO_INTERVENTION
- label
- 4. Pancreas cancer - control
- description
- Pancreas cancer patients do not administration of COX inhibitor
- type
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * The patients who underwent operation for extrahepatic bile duct cancer or pancreas cancer * Between 19 and 70 years old * Agreed to consent sheet Exclusion Criteria: * The patients cannot administration of drug due to severe postoperative morbidities. * Preexisting heart disease: Ischemic heart disease, Heart failure. Severe uncontrolled hypertension (systolic BP\>160) * Renal insufficiency: CCR \< 50 or serum creatinin \>3.0 * Hepatic insufficiency: Liver cirrhosis or active hepatitis * Preexisting allergic reaction history for NSAIDs or Sulfonamide * Current drug intake: Warfarin. Lithium, Fluconazole, Aspirin, Celecoxib * Preexisting Asthma. Especially aspirin-sensitive asthma. * Contraindications to aspirin, clopidogrel or celecoxib * When patients refused * Patients has psychological problem
References
Publications (1)
- RESULTKoo BK, Kim YS, Park KW, Yang HM, Kwon DA, Chung JW, Hahn JY, Lee HY, Park JS, Kang HJ, Cho YS, Youn TJ, Chung WY, Chae IH, Choi DJ, Oh BH, Park YB, Kim HS. Effect of celecoxib on restenosis after coronary angioplasty with a Taxus stent (COREA-TAXUS trial): an open-label randomised controlled study. Lancet. 2007 Aug 18;370(9587):567-74. doi: 10.1016/S0140-6736(07)61295-1. PMID 17707751